Introduction
Prostate cancer is the most frequently diagnosed nonskin cancer in men in the USA. 1 The majority of prostate cancers are slow-growing, but a subset of them can have an aggressive clinical course and lead to death. A number of autopsy studies noted that there was a disproportionate number of prostate cancers that never caused any symptoms. 2, 3 This was intriguing and unusual for cancer, and the identification of which patients have clinically significant prostate cancer has been at the centre of prostate cancer research for decades. In 1994, Epstein et al. published the first criteria for defining clinically significant prostate cancer, and developed a prediction model to determine which patients would not need definitive therapy. 4 More recently, the results of large randomised clinical trials have confirmed that a great proportion of cancers diagnosed through prostate-specific antigen (PSA) screening are clinically insignificant. 5, 6 These studies have raised awareness, and more patients with prostate cancer considered to be 'clinically insignificant' have been enrolled in protocols for active surveillance (AS), a management option that avoids or delays the side effects of treatments without significantly compromising survival.
With the increased acceptance of AS, the number of patients deferring therapy and living with the disease is increasing, so the definition of 'clinically significant prostate cancer' is more important than ever. 9, 10 Here, we review the studies leading to the definition of 'significant prostate cancer' at radical prostatectomy (RP), and then summarise the findings at needle biopsy that have been used to predict significant cancer and to establish criteria for AS. We also review studies that have tried to expand this definition to enable more patients be safely spared unnecessary treatment.
Significant Prostate Cancer at RP
Significant cancer at RP was initially defined at Johns Hopkins as an index tumour at RP with a volume of >0.2 cm 3 , Gleason grade >7, or extracapsular extension. 4 There is a high incidence of multifocality of prostate cancer, where adding the volumes of many small prostate cancers to a <0.2-cm 3 index tumour would result in a volume of >0.2 cm 3 . There is no evidence that these smaller multifocal tumours impact on the prognosis of the index tumour. It is critical, when reviewing articles on the definition of significant cancer at RP, to note whether the authors only include the index tumour nodule's tumour volume, because, in some cases, summing the volumes of the components of multifocal tumour can misleadingly result in much larger tumour volumes. In the Johns Hopkins original study, a very low tumour volume cutoff of 0.2 cm 3 was accepted as insignificant cancer, and it established a needle biopsy and PSA criteria to predict an RP threshold of 0.5 cm 3 prostate cancer. It is important to put these thresholds in the perspective of the time. This article was the first to propose specific needle biopsy criteria for AS at a time when most authorities were critical of AS, on the grounds that it would lead to undertreatment of prostate cancer. Consequently, it was necessary, if AS was to become acceptable as a treatment paradigm for prostate cancer, for stringent criteria for insignificant cancer to be developed to satisfy critics that only very small prostate cancers would not be treated. In addition to tumour volume, grade, and extraprostatic extension (EPE) have been the three main objective findings used to determine the clinical significance of a tumour. There is general agreement among experts that any tumour with adverse findings at RP should be considered to be clinically significant. Various features have been considered to be adverse, including any one of the following: Gleason score of 4 + 3 =7 or higher [Grade Group (GrG) ≥ 3], non-focal EPE, seminal vesicle invasion, lymph node metastasis, or tumour volume of >2.0 cm 3 .
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The idea that small tumours are clinically less significant than larger ones is a concept of medical oncology that applies to almost any cancer. In the prostate, the size of the tumour was also considered to be an indication of the potential for the tumour to spread outside of the gland and become clinically significant. 11 The thresholds for significant tumour volume were initially established on the basis of cystoprostatectomy studies, in which incidentally found prostate cancer can be seen in up to 54% of cases. [12] [13] [14] [15] [16] Despite the large number of incidentally identified prostate cancers, the chance of a man being diagnosed with clinically significant prostate cancer throughout his lifetime in the USA is 8%. Taking in consideration this small proportion, researchers used this percentage cutoff to establish the minimum volume of prostate cancer that would make it fall in the top 8% and be large enough to be diagnosed during the lifetime of an individual, assuming that tumour volume was the most important variable in the biology of prostate cancer. 12 This study found that 8% of the tumours were >0.5 cm 3 , and this became the new threshold.
Studies on RP specimens found that none of the patients with palpable tumours (clinical T2) with a volume of ≤0.2 cm 3 had EPE or biochemical recurrence (BCR) over a median follow-up of 5 years. 17, 18 In these studies, none of the tumours with a volume of ≤0.2 cm 3 had any cancer with Gleason pattern 4 or 5, but a small proportion of tumours with a volume between 0.2 and 0.5 cm 3 did show Gleason grade 4 or 5 and EPE, so Gleason grade and extension of the tumour were incorporated into the definition of 'minimal' prostate cancer. 4 Many studies have since analysed the threshold for tumour volume of insignificant cancer in RPs with organ-confined tumours and without Gleason pattern 4 or 5. Whereas the initial studies were based on the risk of clinically detectable cancer, in the PSA era 'screening' of detectable prostate cancer was a better representation of reality. A study by Wolters et 3 . Of all RP specimens studied, 53.5% showed organ-confined prostate cancer without Gleason pattern 4 or 5, if the threshold for significance was set at 2.5 cm 3 , and the same calculation method was used. 20 The accuracy of tumour volume measured at RP, and the identification of other adverse findings, including EPE and higher-grade areas, could be influenced by whether the gland was partially or completely submitted. If the gland is partially submitted, the recommendation is to submit the entire posterior lobe, and sample one section from each anterior lobe to rule out a large anterior tumour that would require additional anterior sampling. 21 This method has given the most similar results to those obtained with whole gland submission.
A more recent study tested the hypothesis that an increased tumour volume would increase the risk of BCR. The authors reviewed 1829 prostate cancer patients treated with RP between 1992 and 2008, including 141 (7.7%) patients with a tumour volume of <0.5 cm 3 and 310 (16.9%) patients with a tumour volume between 0.5 and 2.49 cm 3 ; all patients had pure Gleason score 6 (GrG1). 22 Patients with a tumour volume of <0.5 cm 3 had a significantly lower rate of BCR than patients with a tumour volume between 0.5 and 2.49 cm 3 . Furthermore, the group with a tumour volume between 0.5 and 2.49 cm 3 included two patients with cancer-specific death (0.6%), whereas there were no patients with cancerspecific death in the group with a tumour volume of <0.5 cm 3 . Rare cancer-related deaths (0.003%) were also reported in patients with Gleason score 6 (GrG1) tumours in a large study that included >24 000 patients followed for 15 years after RP, although, according to newer data with more current grading, metastases and cancer-related deaths do not occur in patients with pure GrG1. 23, 24 The excellent clinical outcome of patients with prostate cancer with a tumour volume of ≤0.5 cm 3 , with Gleason score 3 + 3 = 6 (GrG1) and without Gleason pattern 4 or 5 has also been validated in many other RP studies, with BCR-free survival after 10 years ranging from 87% to 100%. [25] [26] [27] [28] Regardless of tumour volume, the majority of tumours without Gleason pattern 4 or 5 that are organ-confined will also have an excellent outcome. A study that reviewed 439 RP specimens with pure Gleason 3 + 3 = 6 (GrG1) found that only 3.8% of specimens with a tumour volume of <0.5 cm 3 had EPE or extended to the apex, possibly leading to positive surgical margins. In contrast, 11.1% of specimens with a tumour volume between 0.5 and 2.0 cm 3 had these adverse findings. 29 EPE can, rarely (0.03%), be associated with seminal vesicle invasion in pure Gleason score 6 (GrG1) cancers. 30 Despite local extraprostatic spread, a study that included 14 123 RP specimens from multiple institutions found not a single case of pure Gleason score 6 (GrG1) tumour with metastasis to lymph nodes. 24 Therefore, a tumour of any size with pure Gleason score 6 (GrG1) has an excellent prognosis, with the caveat that there is a direct relationship between tumour volume and EPE that could lead to incomplete resection and local recurrence.
T U M O U R G R A D E I N S I G N I F I C A N T C A N C E R A T R P
Considerations of tumour volume are important, mainly because of its direct correlation with higher grade, EPE, and positive surgical margins. However, when grade, stage and surgical margins are factored in, studies have shown that the clinical significance of the tumour volume is much less important. 18 Grading of prostate cancer has undergone significant changes in recent years. [31] [32] [33] [34] Some of the most relevant changes for the definition of significant prostate cancer are related to the definition of Gleason pattern 4. As Gleason pattern 4 has been redefined, tumours diagnosed with pure Gleason score 6 (GrG1) currently have a better prognosis than prior to the changes in the grading system. 32 Similarly, as many of the tumours previously classified as Gleason score 6 (GrG1) are now graded as Gleason 3 + 4 = 7 (GrG2), the overall prognosis of the latter has also become better. It is important to consider these changes when reviewing older cases, and all cases must be regraded following the current grading systems.
On analysis of RP specimens of patients that would have met the criteria for AS except for a minor component of Gleason pattern 4 at needle biopsy, the rate of adverse findings was significantly higher in this group (21.6%) than in controls, the most common being Gleason grade 4 + 3 = 7 or higher (GrG ≥ 3). 35 As the percentage of Gleason pattern 4 is currently being reported in the diagnosis, 32 ,36,37 a number of research studies have been carried out to establish a category of patients with a 'favourable' prognosis who would benefit from AS. So far, these studies have found that patients with 'favourable' Gleason 3 + 4 = 7 (GrG2) still have a higher risk of Gleason grade 4 + 3 = 7 (GrG), EPE, and seminal vesicle invasion at RP, and a higher risk of BCR, than low-risk men undergoing RP. 38, 39 These studies were performed without consideration of the percentage of Gleason pattern 4 or the different subtypes of Gleason pattern 4, which might have clinical implications for the evaluation of candidates with potential insignificant cancer in the setting of a minor Gleason pattern 4 component. 40 Another important consideration in establishing the significance of prostate cancer at RP is the presence of a tertiary pattern. There is agreement among experts that the presence of minor high-grade patterns adversely affects prognosis. 36 As any percentage of Gleason pattern 4 is now incorporated into the final grade, there is a subset of RP tumours that, in the past, were graded as 3 + 3 = 6 with tertiary pattern 4 (<5%) that are now graded as 3 + 4 = 7 with <5% pattern 4. These constitute the subset of patients considered to have a 'favourable' intermediate risk, in whom the definition of significant cancer is not well established, and probably depends on other factors, including whether or not the tumour is organ-confined, tumour volume, and the life-expectancy of the patient. There is general agreement among experts that no tumour with Gleason score 8-10 or with any amount of Gleason pattern 5 could be considered to be clinically insignificant. 41, 42 E P E A T R P EPE is associated with an increased risk of positive margins and therefore of BCR after RP. [43] [44] [45] [46] [47] It is important to separate cases with focal and non-focal EPE, because the latter group has a much higher risk of BCR. A study that included >10 000 cases divided into three groups, i.e. no EPE, focal EPE (defined as a few extraprostatic cancer glands), and non-focal EPE, found that Gleason grade and the presence of EPE were associated with an increased risk of BCR after RP, and cases with non-focal EPE had a higher risk of BCR than those with focal EPE. 43 In this study, there was also a correlation between EPE and positive margins; patients with no EPE had 6.2% rate of positive margins, versus 27.7% for patients with focal EPE, and 42.1% for patients with non-focal EPE (P < 0.0001). Table 1 shows a summary of the findings that define significant prostate cancer at RP.
Significant Prostate Cancer At Needle Biopsy
Studies analysing RPs have been critical for understanding and predicting the risk of patients with a diagnosis of prostate cancer on needle biopsy, and for establishing criteria for AS. The National Comprehensive Cancer Network (NCCN) categorises patients diagnosed with prostate cancer, by using biopsy grade, clinical stage, and PSA, into those with verylow-risk, low-risk, intermediate-risk, high-risk and very-high-risk prostate cancer (Table 2) . Patients in the very-low-risk, low-risk and favourable intermediate-risk groups are included in the NCCN guidelines as potential candidates for AS. 48, 49 The first criteria for AS, which are known as the Epstein criteria, were adopted as the 'very-low-risk' criteria in the NCCN guidelines, and correspond to one or two cores with cancer Gleason score 3 + 3 = 6 (GrG1), no core with >50% of cancer, and a PSA density of <0.15 ng/ml per cm 3 . 4 This criterion was developed on the basis of a study that reviewed the clinical and pathological characteristics of men who underwent RP for T1c prostate cancer (prostate cancer diagnosed by needle biopsy but without palpable disease), and compared the findings with patients with T1a (incidental diagnosis on transurethral resection of the prostate) and with T2 (palpable tumour) cancers. 4 The three main pathological components establishing eligibility criteria for the different protocols of AS are the number of cores with cancer, percentage of cancer, and cancer grade.
N U M B E R O F P O S I T I V E B I O P S Y C O R E S A S A P R E D I C T O R O F S I G N I F I C A N T C A N C E R
Undersampling of a high-grade tumour in needle biopsy could lead to misclassification of a cancer as insignificant. When the Epstein criteria were developed, the average number of needle cores obtained in a prostate biopsy was six. 4 In an attempt to avoid undersampling, the most common template biopsy performed currently consists of 12 cores. This has raised the question of whether more cores could be allowed to have cancer and still safely predict an insignificant tumour at RP. Studies have shown that increasing the number of cores from six to 10 or 12 by additional lateral sampling correlates with an increased number of cancers being diagnosed. 50 The majority of the cancers detected with these added cores are significant cancers, and this has therefore been established as the standard of care. 51 Saturation biopsy (obtaining between 20 and 60 cores per gland, depending on the size) has been proposed as a mechanism to decrease the number of cases with undersampled higher-grade cancers, 52 but the prediction of insignificant cancer might not improve, or improve only slightly. 52, 53 Another question that often arises regarding the number of cores is whether a higher number of cores with cancer should be allowed when biopsies are performed with more cores. In fact, some AS protocols would consider the threshold of the number of biopsy cores allowed with cancer as a percentage of the total. 54 However, a study based on RP findings showed that a higher number of positive cores is associated with a higher risk of significant cancer and potential undertreatment. 55 However, a different study evaluated adverse findings at RP defined as Gleason score 4 + 3 = 7 or above (GrG ≥ 3), seminal vesicle invasion or lymph node metastasis in patients with low-risk prostate cancer (see Table 2 for the definition of low-risk prostate cancer). The authors found no significant association with the number of positive cores, the extent of cancer in millimetres, or the percentage of any core. However, when the definition of adverse findings was expanded to include patients with Gleason 3 + 4 = 7 (GrG2) and EPE, the association between findings on core biopsies was statistically significant, but was interpreted as 'clinically weak'. 56 Similar observations were made in a Prostate Cancer Research International Active Surveillance study, in which the number of positive cores was not predictive of adverse findings at RP. 49 On regression analysis, this last study found that the only predictor of adverse pathological findings at RP was Gleason score >6 on the last biopsy. Therefore, the literature indicates that, although there is certain correlation between the total number of positive cores and adverse findings at RP, the great majority of these patients still have favourable pathological findings at RP and appear to have long-term results that are comparable to those of patients with up to two positive cores. With the incorporation of magnetic resonance imaging-targeted biopsies, many patients are diagnosed with cancer solely in the area targeted so the addition of cancer in targeted cores would generate a higher number of cores with cancer. We consider multiple cores from the targeted area as one positive core and report them in aggregate, as this has been shown to correlate better with findings at RP. 57 However, there is substantial variability in the way in which clinicians interpret the reports of needle biopsies, and there is a need for more uniform interpretation of the findings to accurately assign the appropriate treatment. A study that surveyed 114 clinicians, including 88 urologists and 26 oncologists, shows that multiple biopsies taken from a single site are often interpreted by clinicians as separate cores when they are establishing the maximum number of cores involved. 58 This study also found that clinicians often do not use a uniform approach in the interpretation of multiple Gleason scores, and the authors have proposed including a single 'bottom-line' Gleason score to each case.
T U M O U R V O L U M E ( P E R C E N T A G E O F C O R E ) O N B I O P S Y A S A P R E D I C T O R O F S I G N I F I C A N T C A N C E R
A maximum limit of 50% in any core with cancer has been established as one of the criteria for verylow-risk cancer, and one that correlates best with insignificant cancer. A study from our institution suggests that unilateral cancer is a better predictor of insignificant cancer than the percentage involvement. 55 In this study, the authors correlated preoperative prediction of insignificant cancer with how often the model misclassified the patient on the basis of increasingly worse categories of significant cancer at RP (Table 3) . They used this categorisation to design modified Epstein criteria for significant cancer at needle biopsy. By using laterality (only one side with cancer), the prediction model significantly decreased the proportion of misclassified cases, especially those leading to the worst outcome, i.e. RP categories 3 and 4. 55 This is an important consideration in patients with targeted biopsies in which the significance of the percentage of tumour involvement is largely unknown. Additionally, consideration of unilateral versus bilateral could be helpful in cases with discontinuous involvement of a core. A study at our institution showed that addition of the intervening benign tissue between two separate foci of cancer correlates better with findings at RP, including organ-confined disease or positive margins, than when only the tissue with tumour is added to the percentage. 59 Patients who have Gleason score 6 (GrG1) cancer but do not meet the criteria of 50% maximum percentage involvement or have more than two cores with cancer are considered to be at low risk according to the NCCN guidelines, and could still be candidates for AS should they meet other low-risk criteria. Our group recently performed a study comparing patients with very-low-risk disease with those with low-risk disease who did not meet all of the very-lowrisk criteria, owing to more than two cores with Gleason score 6 (GrG1) cancer or >50% of tumour involvement, and were enrolled for AS. The biopsy findings were then compared with the biopsy findings of a similar cohort of men who underwent RP. In general, men who underwent RP had a higher number of biopsy cores with cancer (3 versus 1, P < 0.001) and a higher percentage of core involvement (40% versus 10%, P < 0.001). It is of note that patients who underwent RP were also younger (average age of 59 versus 66 years, P < 0.001). 60 This supports the idea of risk stratification in low-risk patients in which tumour volume at biopsy and, possibly, age of the patient are factored in when the decision to undergo RP is made. 61 Table 3 . Increasingly worse categories of significant cancer at radical prostatectomy based on grade, stage, and tumour volume GrG1, TV > 0.5 cm
T U M O U R G R A D E A T N E E D L E B I O P S Y A S A P R E D I C T O R O F S I G N I F I C A N T C A N C E R
A Gleason score of 3 + 4 = 7 (GrG2) or above will exclude a patient from AS in most protocols. 54 As mentioned before, some programmes have considered the inclusion of patients with a small volume of Gleason grade 3 + 4 = 7 (GrG2) tumour, and it is also indicated as a management option in the NCCN guidelines. 62 Few studies have analysed the clinical outcome of patients enrolled for AS with Gleason 3 + 4 = 7 (GrG2) and who were managed expectantly. [63] [64] [65] A study compared patients with low risk and intermediate risk according to the NCCN guidelines, in which there was a subset of patients with Gleason 3 + 4 = 7 (GrG2). It is worth noting that most of the studies consider patients with intermediate risk as a single group, independently of whether they are included because of PSA value or the presence of Gleason 3 + 4 = 7 (GrG2). As a whole, patients with initial low-risk disease had better posttherapy BCR free survival, better overall survival and less frequent distant metastases than those with GrG2. 63, 66 More recently, studies have been performed with the aim of subclassifying the intermediate-risk patients and defining a 'favourable' intermediate-risk group, similar to the definition of favourable intermediate risk for the purpose of radiation therapy. 67, 68 A study based on adverse findings at RP confirmed previous results and emphasised the associated higher risk of adverse findings even in patients classified as having 'favourable' intermediate risk. Furthermore, patients with intermediate risk with Gleason score 6 (GrG1) had fewer adverse findings at RP than those with favourable intermediate risk, in whom the only criterion not meeting those required for inclusion in the low-risk group was the presence of Gleason score 3 + 4 = 7 (GrG2) at biopsy. 35 As mentioned above, the grading system has undergone significant changes in recent years, and, after the redefinition of morphologies associated with Gleason pattern 4, it became evident that patients with Gleason score 3 + 4 = 7 (GrG2) have a much better prognosis than those with Gleason score 4 + 3 = 7 (GrG3). 33, 34 Therefore, it is intuitive to think that gradual increases in the percentage of Gleason pattern 4 will correlate with poorer prognosis. The latest recommendation of the International Society of Urological Pathology and of the World Health Organization is to include the percentage of Gleason pattern 4 involvement, both in the needle biopsies and in RP specimens. 32 Some evidence is starting to emerge that the percentage of Gleason pattern 4 in needle biopsies can predict adverse findings at RP and BCR. For example, a study that divided patients with needle biopsies with cancer Gleason score 3 + 4 = 7 (GrG3) into two subgroups, i.e. those with <5% Gleason pattern 4 and those with 6-50% Gleason pattern 4, found that it helps to predict EPE at RP. 69 A more recent study that included >1600 patients separated into groups of 10% increases of Gleason pattern 4 in needle biopsies correlates with adverse pathological findings at RP both in patients with Gleason score 3 + 4 = 7 (GrG2) and in those with Gleason score 4 + 3 = 7 (GrG3), and with BCR. 70 A separate study that included >1200 patients also divided the patients into groups with increasing percentages of Gleason pattern 4, and found that a higher percentage of Gleason pattern 4 predicts EPE at RP. 71 Therefore, as more studies are being performed, it is possible that the percentage of Gleason pattern 4 will be included in prediction models for significant cancer.
In addition to the percentage of Gleason pattern 4, some recent studies have indicated that the different subtypes of Gleason pattern 4 (poorly formed glands, fused glands, glomeruloid structures, and cribriform glands) have different prognostic implications. 40 Recently published studies have shown that the cribriform pattern is associated with BCR, EPE, positive surgical margins, distant metastasis, and disease-specific death. [72] [73] [74] [75] These studies suggest that the risk assessment of significant cancer should include the morphological subtype of Gleason pattern 4. Table 4 shows a summary of the findings that define significant prostate cancer at needle biopsy.
P E R I N E U R A L I N V A S I O N ( P N I ) A N D E P E I N N E E D L E B I O P S Y A N D S I G N I F I C A N T C A N C E R
Most studies have shown that PNI on needle biopsy is correlated with but not necessarily indicative of EPE in RP. 76, 77 However, most studies have failed to demonstrate that PNI is an independent predictor of poor prognosis. For the purpose of eligibility for AS, studies have shown that needle biopsies with PNI do not correlate with more adverse findings at RP than those without PNI, so PNI should not change eligibility if all other criteria are met. 78, 79 Similarly to that of PNI, the significance of EPE in needle biopsies is controversial. A recently published study demonstrated an association between diseasespecific mortality and PNI (univariate analysis), but there was no association with EPE. 80 It is very unusual to see EPE in the needle biopsy and still meet all other criteria for AS. As mentioned above, EPE is associated with increased risks of BCR and positive margins at RP. 43 In summary, the pathological findings made on prostate needle biopsies have constituted the backbone of prediction models for significant cancer and eligibility criteria for AS protocols. Table 5 shows the different pathological eligibility criteria for some of the AS protocols.
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Conclusions
The current definitions of insignificant cancer at RP and needle biopsy are probably too stringent, but are the safest so far to avoid misclassification and consequent undertreatment. Areas of current and future research in pathology aimed at improving the definition of significant cancer are focused on the significance of the percentage of Gleason pattern 4 as a proportion of the overall cancer, and the architectural subtypes of Gleason pattern 4. The molecular biology of the tumour and the contributions from modern imaging studies are aspects not covered in this article, but will probably impact on the definition of significant prostate cancer in the future.
